Three letters in 2026, one recurring finding
FDA sent warning letters to three separate distributors of perinatal and exosome products during 2026: R3 Medical Companies on August 14, Blue Horizon International LLC on May 26, and Dynamic Stem Cell Therapy on February 11. Each letter addressed a different company, and the underlying finding cited in each was similar.
In each letter, FDA pointed to disease or condition claims made in the company's own marketing, specifically on websites and social media, as evidence that the products were being promoted for uses that exceeded what their regulatory status allowed.
Why website and social content counted as evidence (fda warning letter stem cell exosome)
A common assumption among sellers of regenerative products is that a processing description or a 'research use only' label on the product itself is the controlling document. FDA's 2026 letters treat marketing content as independent evidence of intended use, separate from and in addition to anything printed on the product label.
That means a technically accurate certificate of analysis or processing summary does not offset a landing page, a comparison article, or a social post that names a disease or condition the product is implied to help with. FDA reads the whole promotional footprint, not just the label.
The end of enforcement discretion set the stage
FDA's period of enforcement discretion for certain HCT/P products ended on May 31, 2021. Before that date, FDA allowed additional time for companies marketing certain section 351-pathway products to come into compliance while the agency and industry worked through licensing questions. After that date, promotion of an unapproved biologic product for a clinical use carries the full weight of ordinary enforcement.
The 2026 letters are consistent with that posture continuing years later. The letters cited website and social-media disease claims as evidence of intended use.
What this means if your clinic buys from a distributor
A warning letter addressed to a distributor is not, by itself, a finding against every clinic that purchased that distributor's products. But a clinic's exposure is not limited to what it personally wrote, either. Reviewing a distributor's own website and social content before placing an order gives a clinic an early signal of whether that distributor's regulatory posture matches its marketing.
It is also worth treating a clinic's own marketing as a separate and independently reviewable surface. FDA's intended-use analysis applies to a clinic's website, consult materials, and social presence just as it applies to a distributor's, regardless of who manufactured the product.
What this means if you distribute or resell these products
A practical response to these letters includes a compliance review across every surface that describes the product, including the website, product pages, blog content, social accounts, and affiliate or reseller materials. Each should be checked against the same standard: no disease or condition named, no claim of treating, curing, or improving a condition, and no outcome language.
Research-use-only language should be treated as a factual statement about a product's marketed status, not a shield against other marketing that implies clinical use. If a company's content elsewhere describes clinical application, the RUO label will not change how FDA reads the company's intended use. These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.
Where a product is an exosome or extracellular vesicle preparation specifically: FDA states no exosome products are FDA approved, they are generally regulated as biologic drugs under section 351, and purchase and clinical-use decisions belong to the physician, together with their own regulatory counsel.
Frequently asked questions
What did the 2026 FDA warning letters have in common?+
Each letter, to R3 Medical Companies, Blue Horizon International LLC, and Dynamic Stem Cell Therapy, cited disease or condition claims made on the company's website or social media about perinatal or exosome products.
Does a warning letter mean the underlying product is illegal?+
Not necessarily. The supplied summaries identify disease claims in marketing as a cited issue. They do not establish that marketing was the only issue, and a product's classification is a separate question from how it was promoted.
Can a clinic be affected by its distributor's marketing?+
A clinic's own marketing is reviewed independently, but a distributor whose public claims draw FDA attention is a useful early signal when evaluating a supplier, since the same risk pattern can appear downstream.
What pattern do these letters show repeatedly?+
Disease or condition claims, or implied treatment outcomes, appearing somewhere in a company's promotional footprint, including social media and affiliate content, not only on the product label.